Review of bimekizumab in the treatment of psoriasis

Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these interleukins and the formation of psoriatic plaques. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Koppu, Sindhuja, Singh, Rohan, Kaur, Kiranjit, Feldman, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746354/
https://www.ncbi.nlm.nih.gov/pubmed/36094828
http://dx.doi.org/10.1080/21645515.2022.2119767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746354/
https://www.ncbi.nlm.nih.gov/pubmed/36094828
http://dx.doi.org/10.1080/21645515.2022.2119767

Ejemplares similares